Ongoing Research With PARP Inhibitors in Ovarian Cancer

EP: 1.A History of PARP Inhibitors

EP: 2.Mechanism of Action and Efficacy of PARP Inhibitors in Ovarian Cancer

EP: 3.PARP Inhibitors for Second-Line Maintenance in Ovarian Cancer

EP: 4.Patient Eligibility for the Use of PARP Inhibitors in Ovarian Cancer

EP: 5.ARIEL3 Trial: Exploratory Analysis Data

EP: 6.Monitoring PARP Inhibitors in Ovarian Cancer for Toxicities

Now Viewing

EP: 7.Ongoing Research With PARP Inhibitors in Ovarian Cancer

EP: 8.Second-Line Maintenance Challenges for PARP Inhibitors in Ovarian Cancer

Bhavesh Shah, RPh, BCOP: It’s exciting about what is next. We’ve seen PARP [inhibitors] being pushed more up front. It went from patients who are refractory, to multiple agents, and then now to second-line, first-line, and really pushing it upfront. I think the goal is to have that long-term progression-free survival time to next treatment that you can have for patients. Then, it’s figuring out what we do after a patient has resistance. I think there’s going to be some ongoing research and combination therapies with immunotherapy, and even expanding the 2 different malignancies. Thinking about how active PARP is and looking at the approvals in prostate, breast, ovarian [cancers], where we know that there’s other PARP-sensitive diseases is exciting. I think going into the tumor agnostic area where we have immunotherapy, if you have MSI [microsatellite instability] you’re basically giving patients immunotherapy across any tumor. This is a similar type of movement that we’re going towards: having a tumor agnostic PARP inhibitor where if you have [a] BRCA mutation, whether it be somatic or germline, that there’s going to be essentially any of the PARP inhibitors that would be active in those diseases. It is exciting to see the pipeline expanding and the combination approach. That’s where I think we’re going towards.

This transcript has been edited for clarity.